Pre-IPO Cryofocus Medtech (Shanghai) - The Industry, the Business and the Concerns

437 Views18 Jul 2022 09:04
Cryofocus Medtech’s products do have technical advantages, but the commercialization outlook remains to be seen due to large price reduction after entering NRDL and uncertainties on market acceptance.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x